UID:
edoccha_9961292043702883
Umfang:
1 online resource (703 pages)
Ausgabe:
First edition.
ISBN:
0-443-13211-9
Anmerkung:
Front Cover -- Cancer Stem Cells and Signaling Pathways -- Copyright Page -- Dedication -- Contents -- List of contributors -- Preface -- 1 Origin of cancer stem cells and the signaling pathways associated with stem cells and cancer stem cells -- 1.1 Stem cells -- 1.1.1 Embryonic stem cells -- 1.1.2 Adult stem cells -- 1.1.3 Peripheral blood stem cells -- 1.1.4 Perinatal stem cells -- 1.1.5 Induced pluripotent stem cells -- 1.1.6 Cancer stem cells -- 1.2 Origin of cancer stem cells -- 1.3 Identification of cancer stem cells -- 1.4 Characteristics of cancer stem cells -- 1.5 The molecular similarity in embryonic, induced pluripotent, and cancer stem cells -- 1.6 Embryos and cancer -- 1.7 The JAK/STAT pathway -- 1.8 JAK/STAT pathway in cancer stem cells -- 1.9 MAP kinase pathway in cancer stem cells -- 1.10 Transforming growth factor-β signaling pathway in cancer stem cells -- 1.11 Wnt pathway in cancer stem cells -- 1.12 PI3K/AKT/mTOR pathway in cancer stem cells-the phosphatidyl inositol 3 kinase -- 1.13 Notch signaling -- 1.14 Notch signaling in cancer stem cells -- 1.15 NF-kB pathway -- 1.16 Mutation in NF-kB pathway in cancer stem cells -- 1.17 Mutations in signaling pathways in induced pluripotent stem cells -- 1.18 Chemoresistance in cancer stem cells -- 1.19 Therapeutic targets for cancer stem cell signaling [52] -- 1.20 Conclusion -- References -- 2 The importance of niche in therapeutic strategies targeting normal and cancer stem cells -- 2.1 Introduction -- 2.2 Adult stem cells -- 2.3 Niche and its role in the "stemness" of adult stem cells -- 2.3.1 Major adult stem-cell niches -- 2.3.1.1 Hematopoietic stem-cell niche -- 2.3.1.2 Muscle stem-cell niche -- 2.3.1.3 Cardiac stem-cell niche -- 2.3.1.4 Neural stem-cell niche -- 2.3.2 Common molecular contacts in adult stem-cell niches -- 2.3.2.1 VCAM-1 -- 2.3.2.2 Cadherins.
,
2.3.2.3 Endothelial cell-selective adhesion molecule -- 2.3.2.4 Notch -- 2.3.3 Regenerative therapeutic strategies targeting stem-cell niches -- 2.4 Cancer stem cells -- 2.5 Cancer stem-cell niches -- 2.5.1 Niche cells and factors -- 2.5.1.1 Premetastatic niche -- 2.5.1.2 Cellular plasticity -- 2.5.1.3 Cancer-associated fibroblasts -- 2.5.1.4 Mesenchymal stem cells -- 2.5.1.5 Inflammatory cells -- 2.5.1.6 Angiogenesis and hypoxia -- 2.5.2 Therapeutic strategies targeting cancer stem cell-niche interaction -- 2.6 Conclusions -- Conflict of interest -- Abbreviations -- References -- 3 Cancer stem cell research: a phosphoproteomic approach -- 3.1 Introduction -- 3.2 Protein phosphorylation and phosphoproteomics -- 3.3 Phosphorylation studies of G protein-coupled receptor, CXC chemokine receptor 4, and cancer stem cells in breast cancer -- 3.4 Phosphorylation studies of progesterone receptor, forkhead box protein O1, and cancer stem cells in breast cancer -- 3.5 Phosphorylation studies of casein kinase 2 and cancer stem cells in head and neck squamous cell carcinomas -- 3.6 Phosphorylation studies of aldehyde dehydrogenase 1 family member A1 and cancer stem cells in pancreatic cancer -- 3.7 The crosstalk between cancer stem cells and mesenchymal stem cells -- 3.8 Phosphorylation studies of mesenchymal stem cells in lung cancer -- 3.9 Conclusions and future prospective -- Contributors -- Conflict of interest -- Funding -- References -- 4 Role of mechanotransduction in stem cells and cancer progression -- 4.1 Introduction -- 4.2 Cellular mechanotransduction -- 4.2.1 Cytoskeleton and mechanotransduction inside cells -- 4.2.1.1 Microtubules -- 4.2.1.2 Actin -- 4.2.1.3 Intermediate filament -- 4.2.2 Cytoplasmic mechanotransduction -- 4.2.3 Nuclear mechanotransduction -- 4.3 Molecular mechanism of mechanotransduction.
,
4.3.1 Matrix stiffness in cancer and mechanotransduction -- 4.3.2 Mechanotransduction and integrin signaling -- 4.3.3 Role of myosin II in cancer and mechanotransduction -- 4.4 Stem cells and mechanotransduction -- 4.4.1 Embryonic stem cells and mechanotransduction -- 4.4.2 Mechanotransduction in mesenchymal stem cells -- 4.4.3 Hematopoietic stem cell and mechanotransduction -- 4.5 Mechanotransduction in cancer stem cells and its role in cancer progression -- 4.5.1 Mechanotransduction in cancer stem cells -- 4.5.2 The mechanical stimulus on angiogenesis and apoptosis -- 4.5.3 The mechanical stimulus on metastasis -- 4.5.4 Role of mechanosensitive Piezo ion channel -- 4.6 Conclusion -- Consent for publication -- Availability of data and materials -- Authors' contributions -- Competing interests -- Funding -- References -- 5 Cancer stem cell signaling in neuroblastoma progression-in touch with reality -- 5.1 Introduction -- 5.1.1 Cancer stem cells -- 5.1.2 Neuroblastoma cancer stem cells -- 5.2 Molecular signaling mechanisms involved in neuroblastoma -- 5.2.1 Wnt/β-catenin signaling pathway -- 5.2.2 Transforming growth factor-beta signaling pathway -- 5.2.3 AKT signaling pathway -- 5.2.4 RAS/MAPK signaling pathway -- 5.2.5 MAPK-AKT pathway intersection -- 5.2.6 p38MAPK pathway -- 5.2.7 Anaplastic lymphoma kinase signaling pathway -- 5.2.8 Hedgehog signaling pathway -- 5.2.9 Notch signaling pathway -- 5.2.10 Growth factor signaling cascade -- 5.2.11 Adenosine monophosphate-activated protein kinase pathway -- 5.2.12 Neurotrophins and neurotrophin receptor signaling -- 5.2.13 Hippo signaling pathway -- 5.2.14 PHF20/PARP1 signaling -- 5.2.15 Peroxisome proliferator-activated receptor γ signaling pathway -- 5.2.16 Molecules involved in neuroblastoma cancer stem cells -- 5.3 Conclusion -- Abbreviations -- References.
,
6 Role of cancer stem cells in developing chemoresistance of solid tumor -- 6.1 Introduction -- 6.2 Molecular pathways involved in cancer stem cell proliferation -- 6.2.1 Wnt signaling pathway -- 6.2.2 Hippo pathway -- 6.2.3 Janus kinase/signal transducers and activators of transcription pathway -- 6.2.4 TGF-β signaling pathway -- 6.2.5 Notch pathway -- 6.2.6 Hedgehog pathway -- 6.3 Role of cancer stem cells in drug resistance -- 6.3.1 Multiple drug resistance -- 6.3.2 Metabolism adaptation -- 6.3.3 Apoptotic block -- 6.3.4 Efficient DNA repair -- 6.3.5 Quiescence -- 6.3.6 Alteration of DNA damage repair system -- 6.4 Role of tumor microenvironment in cancer stem cell -- 6.5 Cancer stem cell as a novel target for cancer therapy -- 6.6 Role of claudin proteins in regulation of cancer stem cell and chemoresistance -- 6.7 Role of Nrf2 in chemoresistance -- 6.8 Cancer stemness biomarkers -- 6.8.1 CD44 -- 6.8.2 CD133 -- 6.8.3 CD24 -- 6.8.4 CD47 -- 6.8.5 OCT4 -- 6.9 Conclusion -- Abbreviations -- Reference -- 7 Cell surface markers and signaling pathways of cancer stem cells: target for potent therapeutics -- 7.1 Introduction -- 7.1.1 Stem cells and cancer stem cells -- 7.1.2 Cancer stem cell markers -- 7.2 Cancer stem cell markers in different cancers -- 7.3 Major signaling pathways associated with cancer stem cell -- 7.3.1 JAK/STAT pathway -- 7.3.2 Hedgehog pathway -- 7.3.3 Wnt pathway -- 7.4 The noncanonical pathway -- 7.4.1 Notch pathway -- 7.4.2 PI3K and PTEN pathway -- 7.4.3 NF-kB pathway -- 7.4.4 Implication of cancer stem cells in targeted therapy -- 7.5 Stemness pathways: solid tumor-associated cancer stem cell markers -- 7.5.1 OCT4 -- 7.5.2 ATP-binding cassette superfamily G member 2 -- 7.5.3 Sox2 -- 7.5.4 Notch -- 7.5.5 Nanog -- 7.5.6 CD44 -- 7.5.7 CD133 -- 7.5.8 CD25 -- References.
,
8 Lung cancer stem cells markers and their potential therapeutic molecular targets -- 8.1 Introduction -- 8.2 Lung cancer stem cell surface markers -- 8.2.1 CD133 -- 8.2.2 CD44 -- 8.2.3 Epithelial cell adhesion molecule -- 8.2.4 ATP-binding cassette subfamily G member 2 -- 8.3 Lung cancer intracellular stem cell markers -- 8.3.1 Aldehyde dehydrogenase 1 family member A1 -- 8.3.2 Transcriptional factors -- 8.3.2.1 Octamer-binding transcription factor 4 -- 8.3.2.2 Sex determining Y region-box 2 -- 8.3.2.3 Nanog -- 8.4 Key signaling pathways involved in lung cancer stem cells -- 8.4.1 Hedgehog pathway -- 8.4.2 Notch pathway -- 8.4.3 Wnt/β-catenin pathway -- 8.5 Therapeutic approaches in lung cancer stem cells -- 8.5.1 Antibody drugs targeting lung cancer stem cell markers -- 8.5.2 Chimeric antigen receptor -T cell therapies targeting lung cancer stem cell markers -- 8.6 Conclusion -- References -- 9 Role of cancer stem cells in maintenance of tumor heterogeneity in brain tumors -- 9.1 Introduction -- 9.2 Brain tumor hierarchy and heterogeneity -- 9.3 Cancer stem cells at the epitome of brain tumor cellular hierarchy -- 9.4 Nongenetic factors affecting cancer stem cell plasticity and governing heterogeneity in brain tumors -- 9.4.1 Tumor microenvironment and cancer stem cell niche -- 9.4.2 Epigenetic mechanisms -- 9.4.3 microRNAs and long noncoding RNAs -- 9.5 Genetic factors affecting cancer stem cell plasticity and governing heterogeneity in brain tumors -- 9.5.1 Genetic instability -- 9.5.2 Mutations -- 9.6 Signaling pathways modulating cancer stem cell proliferation in brain tumors -- 9.6.1 Wnt pathway -- 9.6.2 Notch pathway -- 9.6.3 Hedgehog pathway -- 9.6.4 Phosphatidylinositol-3-kinase/Akt pathway -- 9.6.5 Nuclear factor kappa B pathway -- 9.6.6 Receptor tyrosine kinase pathway -- 9.7 Cancer stem cells drive therapy resistance in brain tumors.
,
9.8 Targeting cancer stem cells in brain tumors for effective therapeutic strategies.
Weitere Ausg.:
Print version: Pathak, Surajit Cancer Stem Cells and Signaling Pathways San Diego : Elsevier Science & Technology,c2023 ISBN 9780443132124
Sprache:
Englisch
Bookmarklink
